OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market

A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.

Test tube with blood sample for COVID-19 test, novel coronavirus 2019 found in Wuhan, China

A new report from the US Department of Health and Human Services Office of the Inspector General (OIG) highlights challenges faced by the US Food and Drug Administration and industry alike during the country’s initial struggles with the COVID-19 pandemic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation